K. Fritsch

发表

Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9

J. Finke, C. Grüllich, K. Fritsch, 2013, Annals of Hematology.

Hematopoietic stem cell maintenance in steady-state and inflammation

K. Fritsch, 2017 .

The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis

L. Tebartz van Elst, R. Dersch, D. Endres, 2018, Journal of Neurology.

Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT

G. Zakout, B. Kasenda, F. Burns, 2015, Bone Marrow Transplantation.

High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study

R. Houot, K. Hoang-Xuan, J. Tamburini, 2017, Bone Marrow Transplantation.

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

J. Blay, B. O'neill, K. Hoang-Xuan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness.

M. Lopes, W. Hardt, M. Manz, 2017, Cell stem cell.

Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.

J. Finke, B. Kasenda, G. Illerhaus, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

J. Panse, R. Möhle, J. Finke, 2016, Leukemia.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

J. Finke, E. Valk, E. Zucca, 2016, BMC Cancer.

Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.

J. Finke, B. Kasenda, G. Illerhaus, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project

M. J. van den Bent, J. Doorduijn, L. Fischer, 2013, Haematologica.

Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation

M. Dreyling, G. Hess, S. Krause, 2013, Haematologica.

Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment

M. Manz, Hitoshi Takizawa, Larisa Kovtonyuk, 2016, Front. Immunol..

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.

M. Pfreundschuh, R. Möhle, M. Deckert, 2016, The Lancet. Haematology.

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

S. Balabanov, J. Panse, M. Pfreundschuh, 2012 .

Primary CNS lymphoma--radiation-free salvage therapy by second autologous stem cell transplantation.

B. Kasenda, C. Hader, G. Illerhaus, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

M. Pfreundschuh, R. Möhle, J. Finke, 2017, Leukemia.

MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia.

M. Manz, B. Löwenberg, Hitoshi Takizawa, 2016, Blood.

Humanized hemato-lymphoid system mice

R. Flavell, A. Rongvaux, M. Manz, 2016, Haematologica.

Fate Distribution and Regulatory Role of Human Mesenchymal Stromal Cells in Engineered Hematopoietic Bone Organs

P. Bourgine, I. Martin, T. Schroeder, 2019, iScience.

Engineered humanized bone organs maintain human hematopoiesis in vivo.

P. Bourgine, I. Martin, T. Schroeder, 2018, Experimental hematology.

Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness.

M. Lopes, W. Hardt, M. Manz, 2020, Cell stem cell.

The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients

D. Lebiedz, H. Veelken, B. Kasenda, 2012, Annals of Hematology.

Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.

G. Nikkhah, J. Finke, M. Prinz, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

18F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma

Wolfgang A Weber, Benjamin Kasenda, M. Mix, 2013, The Journal of Nuclear Medicine.

18 F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma

M. Mix, P. Meyer, W. Weber, 2013 .

Favourable outcomes of poor prognosis diffuse large B‐cell lymphoma patients treated with dose‐dense Rituximab, high‐dose Methotrexate and six cycles of CHOP‐14 compared to first‐line autologous transplantation

R. Mertelsmann, J. Duyster, J. Finke, 2017, British journal of haematology.

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

J. Finke, E. Valk, E. Zucca, 2016, BMC Cancer.

Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness.

M. Lopes, W. Hardt, M. Manz, 2017, Cell stem cell.